LEO Pharma

LEO Pharma and DKSH Partner to Deliver Products and Solutions to People in Asia with Skin Conditions and Thrombosis

Share
LEO Pharma and DKSH have entered into an agreement to bring high-quality therapeutic products for dermatology and thrombosis to patients across Asia. This agreement both supports LEO Pharma’s strategy of building a simpler and more competitive organization and DKSH Business Unit Healthcare’s strategic focus of strengthening its regional footprint.

Ballerup, Denmark, and Bangkok, Thailand, September 29, 2022– DKSH Business Unit Healthcare, a leading partner for healthcare companies seeking to grow their business in Asia and beyond, has partnered with LEO Pharma to bring high-quality therapeutic products for dermatology and thrombosis to patients across Asia.

Partnering in Hong Kong, Malaysia, Singapore, Taiwan, Thailand, Vietnam, and the Philippines, the two companies seek to solidify brand presence, grow market share, and ultimately improve patient health outcomes in the region.Skin diseases can cause serious physical and social discomfort for millions of patients around the world whereas thrombosis can affect anyone regardless of their age, race, gender, and ethnicity.

DKSH will support LEO Pharma by building dedicated sales and marketing teams on the ground in Asia and managing logistics and product distribution in these markets. The firm’s experienced teams and broad distribution network will ensure LEO Pharma products reach modern trade, traditional trade, hospitals, clinics, and other medical channels, as well as patients in need across the region.

LEO Pharma is a global company dedicated to advancing the standard of care for the benefit of people with skin conditions, their families and society. With decades of research and development to advance the science of dermatology, LEO Pharma now offers a wide range of innovative treatments and therapies for all skin disease severities as well as thrombosis.

Khalid Aouidat, Vice President, responsible for commercial activities in Southeast Asia at LEO Pharma commented: “At LEO Pharma, we are dedicated to changing the standards of care for people with skin diseases by bringing new innovative treatments forward and making them easily accessible. Supporting this ambition, we are delighted to be partnering with DKSH. Their experience and strong regional footprint in Asia, as well as their marketing and sales expertise should help to further strengthen LEO Pharma’s brand and its continued growth.”

Bijay Singh, Head of Business Unit Healthcare at DKSH, said: “We are committed to enriching people’s lives and improving healthcare for all. The partnership with LEO Pharma strengthens our ambition to become the preferred partner for clients to help patients in Asia to have better access to high-quality and innovative products and solutions. While we drive their growth across the region, LEO Pharma can focus on researching and developing products and solutions for people with skin conditions.”

Contacts

DKSH Business Unit Healthcare
Sheena Flannery
Director, Group Marketing
sheena.flannery@dksh.com


LEO Pharma
Henrik Heskjær
hdtdk@leo-pharma.com

Images

About LEO Pharma

LEO Pharma
LEO Pharma
Industriparken 55
2750 Ballerup

4494 5888http://www.leo-pharma.com/

About LEO Pharma

LEO Pharma is a global company dedicated to advancing the standard of care for the benefit of people with skin conditions, their families and society. Founded in 1908 and majority owned by the LEO Foundation, LEO Pharma has devoted decades of research and development to advance the science of dermatology, and today, the company offers a wide range of therapies for all disease severities. LEO Pharma is headquartered in Denmark with a global team of 5,200 people, serving millions of patients across the world. In 2021, the company generated net sales of EUR 1,339 million. www.leo-pharma.com

 

About DKSH

DKSH’s purpose is to enrich people’s lives. For more than 150 years, we have been delivering growth for companies in Asia and beyond across our Business Units Healthcare, Consumer Goods, Performance Materials, and Technology. As a leading Market Expansion Services provider, we offer sourcing, market insights, marketing and sales, eCommerce, distribution and logistics as well as after-sales services. DKSH is a participant of the United Nations Global Compact and adheres to its principles-based approach to responsible business. Listed on the SIX Swiss Exchange, DKSH operates in 36 markets with 33,100 specialists, generating net sales of CHF 11.1 billion in 2021. The DKSH Business Unit Healthcare distributes pharmaceuticals, consumer health and over-the-counter (OTC) products as well as medical devices. With around 7,920 specialists, the Business Unit generated net sales of CHF 5.6 billion in 2021. www.dksh.com/hec

Subscribe to releases from LEO Pharma

Subscribe to all the latest releases from LEO Pharma by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from LEO Pharma

LEO Pharma and the Parker Institute Partner to Advance Skin Disease Research14.4.2025 10:00:00 CEST | Pressemeddelelse

LEO Pharma and the Parker Institute have entered a 3-year partnership with the objective to advance dermatology research. The collaboration will leverage the Parker Institute’s expertise in trial design, artificial intelligence, and SingleCell RNA sequencing and LEO Pharma’s global leadership in serving 90 million patients annually in medical dermatology to enhance understanding and treatment of skin diseases. This initiative reinforces LEO Pharma's commitment to unlock external innovation and drive standard of care improvement. Ballerup, Denmark, 14 April 2025 – LEO Pharma and the Parker Institute at Copenhagen University Hospital have formed an academic partnership to advance research and innovation in medical dermatology. This collaboration aims to produce high-quality research that enhances disease understanding and benefits patients. Furthermore, it aims to discover molecules that could potentially be integrated into broader pharmaceutical research and development efforts. “We are

LEO Pharma Presents New Late-Breaking Delgocitinib Cream Data For the Third Consecutive Year at AAD 20258.3.2025 17:45:38 CET | Pressemeddelelse

The post hoc analysis investigated treatment responses in a patient subgroup with moderate to severe Chronic Hand Eczema (CHE) treated with delgocitinib cream for 16 weeks in the DELTA 1 2 phase 3 trials.(1) Late-breaking presentation showcased that delgocitinib cream produced a deep, consistent and/or maintained response in a subgroup of patients with moderate to severe Chronic Hand Eczema (CHE).(1) Separate data presented at the American Academy of Dermatology (AAD) 2025 Annual Meeting evaluated systemic exposure in patients following high use of delgocitinib cream to treat moderate to severe CHE.(2)

Liisa Hurme and Mark Levick elected to LEO Pharma’s Board of Directors5.3.2025 10:00:00 CET | Pressemeddelelse

At LEO Pharma’s Annual General Meeting 5 March 2025, Liisa Hurme, President and CEO of Orion Corporation, and Mark Levick, former EU medicines regulator and CEO of Alvotech, were elected as independent members of the Board of Directors. Liisa Hurme brings over 20 years of experience in the chemical and healthcare industries, with expertise in R&D, business development, global supply chains, and operations. She joined Orion Corporation in 1999 and became President and CEO in 2022. Liisa also chairs the Board at the Chemical Industry Federation of Finland and has served on various company and industry boards. She holds a doctorate in biochemistry from the University of Helsinki. Mark Levick is a former EU medicines regulator and CEO of Alvotech, a global biopharmaceutical company listed on the US NASDAQ. His expertise was gained through a successful career as a practicing specialist physician in Australia and the UK, before leading global R&D groups at GlaxoSmithKline and Novartis in the

LEO Pharma delivers double-digit revenue growth and strong progress for strategic transformation26.2.2025 09:00:00 CET | Pressemeddelelse

Ballerup, Denmark, 26 February, 2025 – LEO Pharma delivered another year of strong progress in 2024, with both sales growth and adjusted EBITDA margin ahead of the initial outlook for the year, putting the company on track to meet its profitability targets and to achieve its long-term strategic objectives. “2024 was a year of strong progress for LEO Pharma with double-digit growth in sales and another year of significantly improved EBITDA. A major highlight in 2024 was the approval and launch of our pioneering innovative topical Anzupgo® for chronic hand eczema (CHE). Additionally, we have strengthened our pipeline and successfully implemented efficiency initiatives set to substantially further improve our financial performance in 2025 and return LEO Pharma to a positive net result. With our innovative portfolio demonstrating significant commercial potential, and by maintaining financial discipline, delivering consistent high growth, and building an attractive pipeline, we are creating

DEBRA Research and LEO Pharma Announce Strategic Partnership to Advance Treatments for Rare Skin Diseases5.2.2025 09:00:00 CET | Pressemeddelelse

Partners form non-exclusive collaboration to expand research efforts and develop new treatments for Epidermolysis Bullosa (EB). The partnership leverages DEBRA Research’s focus on patient care and pharma experience and LEO Pharma’s extensive medical dermatology experience. Munich, Germany, and Ballerup, Denmark, 5 February 2025 – DEBRA Research GmbH, a non-profit organization dedicated to advancing research, advocacy, and support for those affected by Epidermolysis Bullosa (EB) and LEO Pharma, a global leader in medical dermatology, today announced a non-exclusive strategic partnership. This collaboration aims to enhance scouting capabilities and provide additional capacity to accelerate the development of life-changing therapies for EB. The partners are committed to driving transformative progress for EB patients and their families, and to deliver innovative medicines for this serious skin disease with no approved treatment options. “We are pleased to announce our non-exclusive partne

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
World GlobeA line styled icon from Orion Icon Library.HiddenA line styled icon from Orion Icon Library.Eye